Transdermal Delivery Form Disposal Systems and Methods

• US 20080226702A1
• Filed: 03/14/2008
• Published: 09/18/2008
• Est. Priority Date: 03/16/2007
• Status: Abandoned Application

• Current Assignee: Endo Pharmaceuticals Incorporated (Endo International PLC)
• Original Assignee: Endo Pharmaceuticals Incorporated (Endo International PLC)
• Inventors: Goldberg, Alan Philip
• Application Number:
  US12/048,771
• Publication Number:
  US 20080226702A1
• Time in Patent Office: Days
• US Class Current: 424/449
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/4535 containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: B09B 2101/68 Transdermal patches
• CPC Class Codes: B09B 3/0075 Disposal of medical waste casings for used articles, e.g. sharps A61B50/362; sterilisation of refuse A61L11/00; disposal of used needles or syringes A61M5/3205; disintegrating medical waste B02C19/0075

Abstract

The extraction and use of residual opioids from transdermal dosage forms can be reduced by placement and fixation of used dosage forms onto a surface. The used dosage form can be fixed to the surface such that it cannot be removed without at least partially destroying the matrix containing the opioid, or such that the matrix containing the opioid is rendered at least partially inaccessible to opioid extraction methods. The disposal system for one or more opioid-containing transdermal delivery forms comprises at least one disposal surface for receiving the transdermal delivery form. The at least one disposal surface can comprise one or more structures for fixing a transdermal delivery form to the at least one surface. Alternatively, the transdermal delivery form comprises one or more structures for permanently fixing the transdermal delivery form to the surface. The disposal system can also be used for preventing or reducing diversion of opioids from transdermal delivery forms.

Claims

1. A disposal system for one or more used transdermal delivery forms containing controlled substances, comprising at least one disposal surface for receiving the one or more used transdermal delivery forms and one or more structures for fixing the transdermal delivery form to the disposal surface.

2. The disposal system of claim 1, wherein the one or more structures for fixing the used transdermal delivery form to the disposal surface are located on or attached to the at least one disposal surface.

3. The disposal system of claim 1, wherein the one or more used transdermal delivery forms comprise a reservoir for the controlled substance.

4. The disposal system of claim 1, wherein the one or more structures for permanently fixing the transdermal delivery form to the disposal surface are located on or attached to the one or more used transdermal delivery forms.

5. The disposal system of claim 1, wherein the one or more used transdermal delivery forms comprise an opioid.

6. The disposal system of claim 5, wherein the opioid is selected from the group consisting of alfentanil, buprenorphine, butorphanol, codeine, dezocine, dihydrocodeine, fentanyl, fentanyl congeners, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, tilidine, tramadol, the pharmaceutically acceptable acid addition salts thereof, and any combinations of these.

7. The disposal system of claim 6, wherein the fentanyl congeners are at least one selected from the group consisting of sufentanil, alfentanil, lofentanil, carfentanil, remifentanil, trefentanil and mirfentanil.

8. The disposal system of claim 1, wherein the one or more used transdermal delivery forms further comprise a salicylate, acetaminophen, phenylpropanolamine, phenylephrine, chlorpheniramine, caffeine or guaifenesin.

9. The disposal system of claim 1, wherein the one or more used transdermal delivery forms comprise adhesive disposed on substantially the entire surface intended to contact the skin or disposed around substantially the entire perimeter of the surface intended to contact the skin.

10. The disposal system of claim 1, wherein the at least one disposal surface comprises one or more defined areas for receiving the one or more used transdermal delivery forms.

11. The disposal system of claim 10, wherein the defined areas are identified by markings which correspond with the one or more transdermal delivery forms.

12. The disposal system of claim 1, wherein the one or more structures for fixing the transdermal delivery form to the disposal surface comprise one or more adhesives disposed on the at least one disposal surface.

13. The disposal system of claim 1, wherein the one or more structures for fixing the transdermal delivery form to the disposal surface comprise a fastening device.

14. The disposal system of claim 1, wherein the one or more structures for fixing the transdermal delivery form to the disposal surface comprise at least one covering layer.

15. The disposal system of claim 14, wherein the at least one covering layer comprises one or more adhesives.

16. The disposal system of claim 1, wherein the used transdermal delivery forms comprise at least one substance which reduce the oral, intranasal or parenteral effectiveness of controlled substances extracted from the used transdermal delivery forms.

17. The disposal system of claim 16, wherein the substance is an opioid antagonist, capsaicin or a capsaicinoid.

18. A method of disposing of one or more used transdermal delivery forms containing controlled substances comprising:

(1) providing the disposal system of claim 1;

(2) placing one or more used transdermal delivery forms on the at least one disposal surface; and

(3) fixing the one or more used transdermal delivery forms to the at least one disposal surface.

19. A method to reduce or prevent diversion of controlled substances contained in one or more used transdermal delivery forms, comprising:

(1) providing the disposal system of claim 1;

(2) placing one or more used transdermal delivery forms on the at least one disposal surface; and

(3) fixing the one or more used transdermal delivery forms to the at least one disposal surface.

20. A method of producing a disposal system for one or more used transdermal delivery forms containing a controlled substance comprising:

forming at least one disposal surface for receiving the one or more used transdermal delivery forms; and

associating the one or more structures for fixing the one or more used transdermal delivery forms to the at least one disposal surface with the at least one disposal surface.